​Barbara Binzak Blumenfeld, shareholder in the firm's FDA & Biotechnology practice, comments in the Kaiser Health News' article about critics' concern about the explosion in controversial stem cell procedures offered by clinics and, increasingly, respected hospitals. Barbara highlights the FDA's attempts to shut down clinics that offer unapproved stem cell therapies.

Although doctors usually need preapproval to treat patients with human cells, the FDA has carved out a handful of exceptions, as long as the cells meet certain criteria, said Barbara Binzak Blumenfeld, an attorney who specializes in food and drug law at Buchanan Ingersoll & Rooney in Washington.

Read "Elite Hospitals Plunge Into Unproven Stem Cell Treatments."

PBS also ran the story: "Why Expensive, Unproved Stem Cell Treatments Are a New Health Care Trend"